Human medicines European public assessment report (EPAR): Infanrix Hexa, diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed), Date of authorisation: 23/10/2000, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Date of authorisation: 04/01/2007, Revision: 29, Status: Authorised

PSUSA/00001516/202506

PSUSA/00010291/202506

Human medicines European public assessment report (EPAR): Jentadueto, linagliptin,metformin hydrochloride, Date of authorisation: 19/07/2012, Revision: 25, Status: Authorised

CVMP recommendations on limited market classification and eligibility for authorisation under Article 23

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Foscan, temoporfin, Date of authorisation: 24/10/2001, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Fosavance, alendronic acid,colecalciferol, Date of authorisation: 24/08/2005, Revision: 31, Status: Authorised